Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4684-4691

  Lashford, L S ^a   Thiesse, P ^a   Jouvet, A ^a   Jaspan, T ^a   Couanet, D ^a   Griffiths, P D ^a   Doz, F ^a   Ironside, J ^a   Robson, K ^a   Hobson, R ^a   Dugan, M ^a   Pearson, A D J ^a   Vassal, G ^a   Frappaz, D ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; TEMOZOLOMIDE;

ADOLESCENT; ADULT; ARTICLE; BIOPSY; BONE MARROW SUPPRESSION; BRAIN STEM; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; MALE; MORTALITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; THROMBOCYTOPENIA;

EID: 0037115615     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.141     Document Type: Article

References (42)

1. Barkovich AJ, Krischer J, Kun LE, et al: Brain stem gliomas: A classification based on magnetic resonance imaging. Pediatr Neurosurg 16:73-83, 1990
2. Kaplan AM, Albright AL, Zimmerman RA, et al: Brain stem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg 24:185-192, 1996
3. Fischbein NJ, Prados MD, Wara W, et al: Radiologic classification of brain stem tumors: Correlation of magnetic resonance imaging appearances with clinical outcome. Pediatr Neurosurg 24:9-23, 1996
4. Albright AL, Packer RJ, Zimmerman R, et al: Magnetic resonance scans should replace biopsies for diagnosis of diffuse brain stem gliomas. A report from the Children's Cancer Study Group. Neurosurgery 33:1026-1030, 1993
5. Freeman CR, Krischer JP, Sanford RA, et al: Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: A Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 27:197-206, 1993
6. Packer RJ, Boyett JM, Zimmerman RA, et al: Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. Cancer 74:1827-1834, 1994
7. Lewis J, Lucraft H, Ghokal A: A UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. Int J Radiat Oncol Biol Phys 38:925-929, 1998
8. Davis FG, Freels S, Grutsch J, et al: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumour histological type: An analysis based on Surveillance Epidemiology and End Results (SEER) data 1973-1991. J Neurosurg 88:1-10, 1998
9. Marchese MJ, Chang CH: Malignant astrocytic gliomas in children. Cancer 65:2771-2778, 1990
10. Wisoff JH, Boyett JM, Berger MS: Current neurosurgical management and the impact of extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial CCG-945, J Neurosurg 89:52-59, 1998
11. DeAngelis LM, Burger PC, Green SB, et al: Malignant glioma: Who benefits from adjuvant chemotherapy? Ann Neurol 44:691-695, 1998
12. Newlands ES, Stevens MF, Wedge SR, et al: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61, 1997
13. Marzolini C, Decosterd LA, Shen F, et al: Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous and hepatic intra-arterial administration. Cancer Chemother Pharmacol 42:433-440, 1998
14. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumour xenografts. Cancer Res 55:2853-2857, 1995
15. Sankar A, Thomas DG, Darling JL: Sensitivity of short term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10:179-185, 1999
16. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC362856). Br J Cancer 65:287-291, 1992
17. Estlin EJ, Lashford LS, Ablett S. et al: Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 78:652-661, 1998
18. O'Reilly SM, Newlands ES, Glaser MG, et al: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A:940-942, 1993
19. Karnofsky DA, Abelman NH, Craver LF, et al: The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1:634-656, 1948
20. Lansky SB, List MA, Lansky LL, et al: The measurement of performance status in childhood cancer patients. Cancer 60:1651-1656, 1987
21. Gehan EA: The determination of the number of patients required in a preliminary and a disease follow up trial of a new chemotherapy agent. J Chronic Dis 13:346-353, 1961
22. Duffner PK, Krischer JP, Burger PC, et al: Treatment of infants with glioma: The Pediatric Oncology Group experience. J Neurooncol 28:245-256, 1966
23. Gilles FH, Sobel EL, Tavare CJ, et al: Age related changes in diagnoses, histological features and survival in children with brain tumors 1930-1979: The Childhood Brain Tumour Consortium. Neurosurgery 37: 1056-1068, 1995
24. Khatib ZA, Heideman RL, Konvar EH, et al: Predominance of pilocytic histology in dorsally exophytic brain stem tumors. Pediatr Neurosurg 20:2-10, 1994
25. Robertson PL, Muraszko KM, Brunberg JA, et al: Pediatric midbrain tumors: A benign subgroup of brain stem gliomas. Pediatr Neurosurg 22:65-73, 1995
26. Yung WK, Prados MD, Yaya Tur R. et al: Multicentre phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762-2771, 1999
27. Krouwer HG, van-Duinen SG, Kamphorst W, et al: Oligoastrocytomas: A clinicopathological study of 52 cases. J Neurooncol 33:223-238, 1997
28. Ojeda VJ, al-Moutaery KR: Neuropathological biopsy diagnoses in clinical practice: How thorough and reproducible are they? Pathology 30:328-329, 1998
29. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755-764, 1997
30. Von Deimling A, Louis DN, Amman K, et al: Association of epidermal growth factor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77:295-301, 1992
31. Maintz D, Fielder K, Koopman J, et al: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 56:1098-1104, 1997
32. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
33. Bower M, Newlands ES, Blehan NM, et al: Multicentre phase II trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother Pharmacol 40:484-488, 1997
34. Packer RJ: Brain stem gliomas: Therapeutic options at time of recurrence. Pediatr Neurosurg 24:211-216, 1996
35. Middlemas DS, Stewart CF, Kirstein MN: Biochemical correlates of temozolomide sensitivity in paediatric solid tumour xenograft models. Clin Cancer Res 6:998-1007, 2000
36. 6 methylguanine-DNA alkyltransferase activity on chlorethylnitrosourea chemotherapy in brain tumors. Int J Cancer 55:76-81, 1993
37. 6-Methylguanine DNA methyltransferase protein levels in pediatric tumors. Clin Cancer Res 3:2459-2463, 1997
38. Bobola MS, Berger MS, Ellenbogen RG, et al: O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: Relation to patient and tumor characteristics. Clin Cancer Res 7:613-619, 2001
39. Friedman HS, Kokkinakis DM, Pluda J, et al: Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570-3575, 1998
40. Kokkinakis DM, Bocangel DB, Schold SC, et al: Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumour xenografts to treatment with 1,3- bis(2-chlorethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421-428, 2001
41. Reese JS, Koc ON. Lee KM, et al: Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2 chlorethyl)-1-nitrosourea. Proc Natl Acad Sci U S A 93:14088-14093, 1996
42. Chinnasamy N, Rafferty JA, Hickson I, et al: Chemoprotective gene transfer II: Multilineage in vivo protection of haemopoeisis against the effects of an antitumour agent by expression of a mutant O6-alkylguanine-DNA alkyltransferase. Gene Ther 5:842-847, 1998